US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 1.32 against a street estimate of 1.11 — a beat of 18.9%.
Analysts rate Lantheus Holdings Inc a strong buy (12 buy, 1 hold, 0 sell out of 13) with an average price target of $107.74.
| Fund | Stake |
|---|---|
| BlackRock Inc | 12.53% |
| Farallon Capital Management, L.L.C. | 8.55% |
| HHG PLC | 7.31% |
| FMR Inc | 7.09% |
| Vanguard Portfolio Management, LLC | 4.86% |
| Vanguard Capital Management, LLC | 4.46% |
| American Century Companies Inc | 4.31% |
| State Street Corp | 3.72% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 LANTHEUS HOLDINGS, INC. - 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Q2 2026 Revenue: $388.2 million (up 2.7% vs. Q2 2025: $378.0 million) • Six-Mont | 2026-08-06 |
| Results announced · Q3 2026 LANTHEUS HOLDINGS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Worldwide revenue: $388.2 million in Q2 2026, up 2.7% vs. $378.0 million in Q2 2025 • | 2026-08-06 |
| Material agreement · Q3 2026 LANTHEUS HOLDINGS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Acquisition price: $102.50 per share in cash plus one Contingent Value Right (CVR) worth up | 2026-08-04 |
| Reg FD disclosure · Q3 2026 LANTHEUS HOLDINGS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Merger Agreement executed: August 3, 2026 between Lantheus Holdings, Inc., Curium US Holdin | 2026-08-03 |
| Quarterly report · Q1 2026 LANTHEUS HOLDINGS, INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Revenues: $377.3 million (Q1 2026) vs. $372.8 million (Q1 2025), +1.2% growt | 2026-05-07 |
| Results announced · Q2 2026 LANTHEUS HOLDINGS, INC. – Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q1 2026 worldwide revenue: $377.3 million (up 1.2% versus Q1 2025's $372.8 mi | 2026-05-07 |
| Proxy statement · Q2 2026 LANTHEUS HOLDINGS, INC. — 2026 PROXY SUMMARY CEO COMPENSATION • Mary Anne Heino serves as Executive Chairperson and Interim Chief Executive Officer | 2026-03-20 |
| Annual report FY2025 LANTHEUS HOLDINGS, INC. — 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market capitalization (as of June 30, 2025): $4,274.70 million • Stoc | 2026-02-26 |
Readable in the app.
| Announcement | Date |
|---|---|
| Entered into definitive agreement to merge with Curium for $8.0 billion Lantheus Holdings reported Q2 2026 results with mixed financial performance. Revenue grew modestly 2.7% to $388.2 million versus Q2 2025, driven by a 5.2% increase in DEFINITY sales ($88.3M) | 2026-08-06 |
| Entered into merger agreement with Curium US Holdings LLC Lantheus Holdings, Inc. announced it has agreed to be acquired by Curium US Holdings LLC in an all-cash merger. Under the deal terms, Lantheus shareholders will receive $102.50 per share in | 2026-08-04 |
| Company to be acquired by Parent in proposed merger transaction Lantheus Holdings is being acquired by a parent company in a merger transaction. The company has paused its previously-announced CEO search process due to this pending acquisition. The 8-K i | 2026-08-03 |
| Full year 2026 revenue and adjusted EPS guidance provided Lantheus, a radiopharmaceutical company, reported solid 2025 results with $1.54 billion in full-year revenue and $6.08 in adjusted earnings per share. Fourth quarter revenue reached $406.8 m | 2026-02-26 |
| Updated full year 2025 revenue and adjusted EPS guidance reflecting acquisition Lantheus Holdings reported Q3 2025 revenue of $384.0 million (up 1.4% year-over-year), but profitability declined significantly. Adjusted earnings per share fell 25.3% to $1.27 from $1.70, w | 2025-11-06 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lantheus Holdings Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.